Narayana Health Q1 FY27 Investor Presentation Shows Strong Revenue Growth
Narayana Health's Q1 FY27 investor presentation reveals consolidated operating revenues of ₹26,836 million, a 78.0% YoY increase. Consolidated EBITDA was ₹5,052 million (18.8% margin), and PAT was ₹2,073 million (7.7% margin). The company continues to expand its operational footprint and invest in digital transformation and ESG initiatives.
The investor presentation provides a comprehensive update on the company's financial health, operational achievements, strategic initiatives, and future outlook, which is highly material for investors.
The announcement shows strong year-on-year revenue growth, improved operational metrics, and continued investment in expansion and digital initiatives, indicating positive performance.
Narayana Hrudayalaya Ltd. (NH) has released its revised Investor Presentation for the quarter ended June 30, 2026 (Q1 FY27), detailing significant operational and financial performance.
The company reported consolidated operating revenues of ₹26,836 million in Q1 FY27, marking a substantial 78.0% year-on-year increase and a 3.5% sequential growth. Consolidated EBITDA stood at ₹5,052 million, with a margin of 18.8%, while Consolidated Profit After Tax (PAT) was ₹2,073 million, achieving a margin of 7.7%. The net debt to equity ratio was reported at 0.42 as of June 30, 2026, with total borrowings less cash and bank balance and investments amounting to ₹19,671 million.
Operationally, the Narayana Institute of Cardiac Sciences in Bengaluru performed 2,137 cardiac surgeries in Q1 FY27, and the Narayana Hospital, Gurugram, operationalized a CUVIS Ortho Robotic System and a Thulium Laser System. The company also highlighted a wide spectrum of robotic surgeries performed across its units.
India operations contributed significantly to the revenue, with domestic revenues reaching ₹12,381 million in Q1 FY27. The company's footprint includes 20 hospitals and heart centers in India with 5,461 operational beds, alongside a network of clinics and diagnostic centers. The business mix shows a strong reliance on domestic walk-in patients (43%), followed by insured patients (33%).
Financially, the Cayman Islands operations reported hospital revenues of US$13,194 million in Q1 FY27, with EBITDA of US$-3.7 million. The United Kingdom operations generated GBP 65.0 million in hospital revenues post-IFRS, with an EBITDA margin of 8.8%.
The presentation also detailed ongoing capital expenditure plans, including significant investments in greenfield projects in Bangalore and Raipur, with a target of adding substantial bed capacity by FY30. Digital transformation initiatives are also a key focus, with advancements in incident management, electronic documentation, and patient experience through the NH patient app, which has crossed over 4 million installs.
Narayana Health's ESG vision, "Health For All," outlines targets for improving access to care, workforce development, and environmental sustainability, including aiming for carbon neutrality by 2040 and optimizing waste management. The shareholding pattern as of June 30, 2026, shows promoter group holding at 63.3%.
What to do with a filing like this
Narayana Hrudayalaya Ltd. filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Narayana Hrudayalaya Ltd.. Read the original for the full detail.